Patient-reported outcome measures for technology assessment: A comparison between three-dimensional conformal and intensity-modulated radiotherapy in prostate cancer

Table 1 Unweighted and weighted description of patient characteristics before treatment, n (%)/mean (SD or SE)

	Unweighted			Weighted
	3D-CRT cohort	IMRT cohort	P value	3D-CRT cohort	IMRT cohort	P value
Age (years)	69.1 (4.8)	69.6 (4.6)	0.470	69.1 (0.5)	69.1 (1.2)	0.975
Smoking status (%)
Never smoked	29 (33.7)	25 (24.3)	< 0.001	29 (33.7)	13 (25.4)	0.614
Current smoker	18 (20.9)	63 (61.2)		18 (20.9)	11 (20.7)
Ex-smoker	39 (45.3)	15 (14.6)		39 (45.3)	28 (53.9)
Prostate volume (cc)	43.2 (22.8)	39.5 (14.1)	0.226	43.2 (2.5)	41.5 (2.2)	0.370
Gleason total	5.3 (1.1)	6.1 (0.3)	< 0.001	5.3 (0.1)	6.1 (0.0)	< 0.001
6 or less (%)	88 (95.7)	93 (87.7)	0.084	88 (95.7)	50 (94.8)	0.794
7 or more (%)	4 (4.3)	13 (12.3)		4 (4.3)	3 (5.2)
Prostate-specific antigen (ng/mL)	6.7 (1.7)	6.2 (1.8)	0.069	6.7 (0.2)	6.3 (0.3)	0.337
T stage (%)
T1c	72 (78.3)	88 (83)	0.505	72 (78.3)	39 (74.6)	0.735
T2a	20 (21.7)	18 (17)		20 (21.7)	13 (25.4)
Risk group (%)
Low	88 (95.7)	92 (86.8)	0.056	88 (95.7)	49 (93.5)	0.531
Intermediate	4 (4.3)	14 (13.2)		4 (4.3)	3 (6.5)
Comorbidity (%)	76 (88.4)	80 (75.5)	0.037	76 (88.4)	43 (81.2)	0.388
Urological history (%)	20 (21.7)	37 (34.9)	0.060	20 (21.7)	13 (24.2)	0.803
Bowel history (%)	22 (23.9)	16 (15.1)	0.164	22 (23.9)	9 (17.2)	0.526

SD in the unweighted columns and SE in the weighted columns. IMRT: Intensity-modulated radiotherapy; 3D-CRT: Three-dimensional conformal radiotherapy.